|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rauh-Hain JA, Krivak TC, Del Carmen MG and
Olawaiye AB: Ovarian cancer screening and early detection in the
general population. Rev Obstet Gynecol. 4:15–21. 2011.PubMed/NCBI
|
|
3
|
Lee JM, Trepel JB, Choyke P, et al: CECs
and IL-8 have prognostic and predictive utility in patients with
recurrent platinum-sensitive ovarian cancer: Biomarker correlates
from the randomized phase-2 trial of olaparib and cediranib
compared with olaparib in recurrent platinum-sensitive ovarian
cancer. Front Oncol. 5:1232015. View Article : Google Scholar
|
|
4
|
Chambers SK, Clouser MC, Baker AF, et al:
Overexpression of tumor vascular endothelial growth factor A may
portend an increased likelihood of progression in a phase II trial
of bevacizumab and erlotinib in resistant ovarian cancer. Clin
Cancer Res. 16:5320–5328. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rankin EB, Fuh KC, Taylor TE, Krieg AJ,
Musser M, Yuan J, et al: AXL is an essential factor and therapeutic
target for metastatic ovarian cancer. Cancer Res. 70:7570–7579.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Higgins CF: ABC transporters: From
microorganisms to man. Annu Rev Cell Biol. 8:67–113. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bear CE, Li CH, Kartner N, Bridges RJ,
Jensen TJ, Ramjeesingh M and Riordan JR: Purification and
functional reconstitution of the cystic fibrosis transmembrane
conductance regulator (CFTR). Cell. 68:809–818. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tizzano EF, Silver MM, Chitayat D,
Benichou JC and Buchwald M: Differential cellular expression of
cystic fibrosis transmembrane regulator in human reproductive
tissues. Clues for the infertility in patients with cystic
fibrosis. Am J Pathol. 144:906–914. 1994.PubMed/NCBI
|
|
10
|
Peng X, Wu Z, Yu L, Li J, Xu W, Chan HC,
Zhang Y and Hu L: Overexpression of cystic fibrosis transmembrane
conductance regulator (CFTR) is associated with human cervical
cancer malignancy, progression and prognosis. Gynecol Oncol.
125:470–476. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu J, Yong M, Li J, Dong X, Yu T, Fu X and
Hu L: High level of CFTR expression is associated with tumor
aggression and knockdown of CFTR suppresses proliferation of
ovarian cancer in vitro and in vivo. Oncol Rep. 33:2227–2234.
2015.PubMed/NCBI
|
|
12
|
He TC, Zhou S, da Costa LT, Yu J, Kinzler
KW and Vogelstein B: A simplified system for generating recombinant
adenoviruses. Proc Natl Acad Sci USA. 95:2509–2514. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
14
|
Schwiebert EM, Benos DJ, Egan ME, Stutts
MJ and Guggino WB: CFTR is a conductance regulator as well as a
chloride channel. Physiol Rev. 79(Suppl): S145–S166.
1999.PubMed/NCBI
|
|
15
|
Xie C, Jiang XH, Zhang JT, Sun TT, Dong
JD, Sanders AJ, Diao RY, Wang Y, Fok KL, Tsang LL, et al: CFTR
suppresses tumor progression through miR-193b targeting urokinase
plasminogen activator (uPA) in prostate cancer. Oncogene.
32:2282–2291. 2291 e1–7. 2013. View Article : Google Scholar
|
|
16
|
Zhang JT, Jiang XH, Xie C, Cheng H, Da
Dong J, Wang Y, Fok KL, Zhang XH, Sun TT, Tsang LL, et al:
Downregulation of CFTR promotes epithelial-to-mesenchymal
transition and is associated with poor prognosis of breast cancer.
Biochim Biophys Acta. 1833:2961–2969. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jacquot J, Tabary O, Le Rouzic P and
Clement A: Airway epithelial cell inflammatory signalling in cystic
fibrosis. Int J Biochem Cell Biol. 40:1703–1715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu Z, Peng X, Li J, Zhang Y and Hu L:
Constitutive activation of nuclear factor KB contributes to cystic
fibrosis transmembrane conductance regulator expression and
promotes human cervical cancer progression and poor prognosis. Int
J Gynecol Cancer. 23:906–915. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Verma IM and Weitzman MD: Gene therapy:
Twenty-first century medicine. Annu Rev Biochem. 74:711–738. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Björklund A, Kirik D, Rosenblad C,
Georgievska B, Lundberg C and Mandel RJ: Towards a neuroprotective
gene therapy for Parkinson's disease: use of adenovirus, AAV and
lentivirus vectors for gene transfer of GDNF to the nigrostriatal
system in the rat Parkinson model. Brain Res. 886:82–98. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brdickova N, Brdicka T, Andera L, Spicka
J, Angelisová P, Milgram SL and Horejsí V: Interaction between two
adapter proteins, PAG and EBP50: A possible link between membrane
rafts and actin cytoskeleton. FEBS Lett. 507:133–136. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Moyer BD, Denton J, Karlson KH, Reynolds
D, Wang S, Mickle JE, Milewski M, Cutting GR, Guggino WB, Li M and
Stanton BA: A PDZ-interacting domain in CFTR is an apical membrane
polarization signal. J Clin Invest. 104:1353–1361. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Martin GS: The hunting of the Src. Nat Rev
Mol Cell Biol. 2:467–475. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Summy JM and Gallick GE: Src family
kinases in tumor progression and metastasis. Cancer Metastasis Rev.
22:337–358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wiener JR, Windham TC, Estrella VC, Parikh
NU, Thall PF, Deavers MT, Bast RC, Mills GB and Gallick GE:
Activated src protein tyrosine kinase is overexpressed in
late-stage human ovarian cancers. Gynecol Oncol. 88:73–79. 2003.
View Article : Google Scholar
|
|
27
|
Pengetnze Y, Steed M, Roby KF, Terranova
PF and Taylor CC: Src tyrosine kinase promotes survival and
resistance to chemotherapeutics in a mouse ovarian cancer cell
line. Biochem Biophys Res Commun. 309:377–383. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wiener JR, Nakano K, Kruzelock RP, Bucana
CD, Bast RC Jr and Gallick GE: Decreased Src tyrosine kinase
activity inhibits malignant human ovarian cancer tumor growth in a
nude mouse model. Clin Cancer Res. 5:2164–2170. 1999.PubMed/NCBI
|
|
29
|
Okada M: Regulation of the SRC family
kinases by Csk. Int J Biol Sci. 8:1385–1397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Knighton DR, Xuong NH, Taylor SS and
Sowadski JM: Crystallization studies of cAMP-dependent protein
kinase. Cocrystals of the catalytic subunit with a 20 amino acid
residue peptide inhibitor and MgATP diffract to 30 A resolution. J
Mol Biol. 220:217–220. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cooper JA, Gould KL, Cartwright CA and
Hunter T: Tyr527 is phosphorylated in pp60c-src: Implications for
regulation. Science. 231:1431–1434. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takeuchi S, Takayama Y, Ogawa A, Tamura K
and Okada M: Transmembrane phosphoprotein Cbp positively regulates
the activity of the carboxyl-terminal Src kinase, Csk. J Biol Chem.
275:29183–29186. 2000. View Article : Google Scholar : PubMed/NCBI
|
